NSCLC patients with uncommon EGFR alterations confer response heterogeneity to diverse EGFR-tyrosine kinase inhibitors (TKIs), with a generally poor response to first-generation (1G) EGFR-TKIs, but with a favorable response to second-generation (2G) or third-generation (3G) TKIs (Chiu et al., 2015; Xu et al., 2016; Chen et al., 2017; Cho et al., 2020). This evidence concerns the gene EGFR and non-small cell lung carcinoma.